Posts Tagged ‘GLP-1 agonists’

Amgen Bringing More Competition into Obesity

December 5, 2022 — Move over, Novo Nordisk and Eli Lilly. Amgen wants a piece of the action in obesity treatment. With some obvious pride of accomplishment, Amgen unveiled results from a phase 1 study of its dual action conjugate on Saturday. This new experimental drug, AMG 133, is a molecule that combines peptides to activate GLP-1 receptors (as […]

Sensational Headlines, Trivializing Obesity

November 16, 2022 — It’s a fact. Media needs your attention. Thus, journalistic standards live in in tension with the temptation for sensational headlines that trivialize a subject like obesity. We’ve seen it before. Yet the current crop of sensational headlines offering a twisted understanding of serious new obesity treatments is especially disappointing. Here’s an example from the supposedly […]

Better Obesity Meds, Murky Supply and Access

October 31, 2022 — One of the themes you will hear when ObesityWeek gets underway tomorrow in San Diego is the dramatic progress that’s coming into view with new obesity drugs. But the picture quickly becomes murky in the real world because of issues with supply and access to these new and improved obesity meds. The access to care […]

Hollywood, HAES, and GLP-1 Agonists

October 15, 2022 — In GQ recently, Will Peischel asked if the world is ready for extremely effective weight-loss drugs. Of course, the simple answer is yes and no. First of all, it’s clear enough that most people don’t really understand these drugs or the condition they treat. Peischel makes that clear right up front when he calls them […]

Pivotal Results for Semaglutide in Obesity

May 14, 2020 — Yesterday the process of a slow reveal began. Novo Nordisk released the first pivotal results in studies of semaglutide for obesity. This new drug, already available for diabetes, has potential to bring us closer to truly effective obesity treatment without surgery. This was merely a first glimpse – topline results from only one of four […]

PIONEER Studies Converge at the ADA Meeting

June 9, 2019 — Some of the most discussed news coming from the American Diabetes Association Scientific Sessions in San Francisco is all about the PIONEER studies of oral semaglutide. This drug is presently under review at FDA for type 2 diabetes. Interest is keen because it will be the first of its class that doesn’t require an injection. […]

Safety and Weight Gain with Drugs for Type 2 Diabetes

December 27, 2018 — How safe is a drug for type 2 diabetes that causes weight gain? This question pops up as we read a big new study of outcomes with second line drugs for type 2 diabetes. That’s because two types of drugs that cause weight gain – basal insulin and sulfonylureas – had a clear link to bad […]